Articles written by: Browning Staff Contributor

Oncology Venture reaches new development milestone with Dovitinib.

Oncology Venture reaches new development milestone with Dovitinib.

Press release Hørsholm, Denmark 12 November 2019 – Oncology Venture A/S (“OV” or the “Company”) today announced that it plans to file its first NDA in 2020 As a result of the news company strategy, OV expects a strong news flow for its three prioritized programs as the Company brings the programs further ahead in the development in 2020. Dovitinib […]

RadNet Reports Third Quarter Financial Results and Reaffirms Previously Announced 2019 Guidance Levels

RadNet Reports Third Quarter Financial Results and Reaffirms Previously Announced 2019 Guidance Levels

Total Net Revenue (“Revenue”) increased 20.9% to $292.7 million in the third quarter of 2019 from $242.1 million in the third quarter of 2018 Adjusted EBITDA(1) increased 7.7% to $41.0 million in the third quarter of 2019 from $38.1 million in the third quarter of 2018  Earnings Per Share was $0.06 per share in the third quarter of 2019 as […]

Galectin Therapeutics Reports Q3 2019 Financial Results

Galectin Therapeutics Reports Q3 2019 Financial Results

NORCROSS, Ga., Nov. 12, 2019 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2019. These results are included in the Company‘s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange […]

LHC Group to Present at Stephens Nashville Investment Conference

LHC Group to Present at Stephens Nashville Investment Conference

LAFAYETTE, La., Nov. 12, 2019 (GLOBE NEWSWIRE) — LHC Group, Inc. (NASDAQ: LHCG) announced today that the Company is presenting at the Stephens Nashville Investment Conference in Nashville, Tenn. on Friday, November 15, 2019 at 9:45 a.m. Central time and a will be available. To access the live webcast and any presentation material, listeners should go to the section of […]

Oncology Venture advancing towards next milestone in its clinical development of 2X-121.

Oncology Venture advancing towards next milestone in its clinical development of 2X-121.

   Company News Hørsholm, Denmark (12 November 2019) – Oncology Venture A/S (“OV” or the Company) today announced an update on the progress of its ongoing U.S. Phase 2 clinical trial for its PARP inhibitor, 2X-121, for the treatment of ovarian cancer, sited at the Dana-Farber Cancer Institute (Boston, MA, U.S.A.). The cancer drug 2X-121 (formerly E7449) is a small […]